Easier for companies to submit their products for evaluation by the Danish Health Technology Council

Companies are no longer required to meet the cost neutrality requirement when submitting their medical devices and health technologies for evaluation by the Danish Health Technology Council.

The Danish Regions have decided that there will no longer be a requirement for cost neutrality when the Danish Health Technology Council evaluates companies' products in the form of medical devices and health technology.

The requirement for cost neutrality has meant that companies could not submit their products for evaluation by the Danish Health Technology Council if their products was more expensive than their competitors. In those cases, submission had to be made through a hospital or region.

The repeal of the requirement entails that companies can now submit all their products for evaluation by the Danish Health Technology Council, even if the product is more expensive than the alternatives.

However, both public and private applicants are still encouraged to use the Danish Health Technology Council's cost outline to clarify the cost picture, as this will simplify the subsequent assessment of health economics by the Danish Health Technology Council.

The Danish Health Technology Council's evaluations can lead to a positive recommendation for a specific medical device or health technology, which can then lead to the implementation of these products across regions.

You can read the Danish Health Technology Council's news here and about the Danish Health Technology Council's cost outline here.

Want to know more?

If you want to know more, please contact the Plesner's Life Science team.

Latest news on Life Science

Life Science